|
CLL/SLL |
|
B cell prolymphocytic leukemia |
|
Splenic B cell marginal zone lymphoma |
|
Hairy cell leukemia |
|
Splenic B cell lymphoma / leukemia |
|
Lymphoplasmacytic lymphoma |
|
Heavy chain disease |
|
Plasma cell neoplasms |
|
Extranodal marginal zone lymphoma of mucosa associated lymphoid tissue |
|
Nodal marginal zone lymphoma |
|
Follicular lymphoma |
|
Primary cutaneous follicle center lymhoma |
|
Mantle cell lymphoma |
|
Diffuse large B cell lymphoma |
|
DLBCL associated with chronic inflammation |
|
Lymphomatoid granulomatosis |
|
Primary mediastinal large B cell lymphoma |
|
Intravascular large B cell lymphoma |
|
ALK positive large B cell lymphoma |
|
Plasmablastic lymphoma |
|
Large B cell lymphoma - HHV8 associated multicentric Castleman |
|
Primary effusion lymphoma |
|
Burkitt lymphoma |
|
B cell lymphoma, unclassifiable with features of DLBCL and Burkitt |
|
B cell lymphoma, unclassifiable with features of DLBCL and Hodgkin |
|
| Article |
Notes |
Unfavorable: +1q21, del(13q14), del(17q13),
t(4;14), t(14;16), Hypodiploidy
Favorable: t(11;14), Hyperdiploidy |
|
Mixed studies |
|
Genetic abnormalities and survival in multiple
myeloma: the experience of the Intergroupe
Francophone du Myélome. |
del(13),
t(11;14), t(4;14), hyperdiploidy, MYC translocations, and del(17p) |
|
CD200 is a new prognostic factor in
multiple myeloma. |
CD200 |
|
Chromosomal aberrations +1q21 and del(17p13) predict
survival in patients with recurrent multiple myeloma
treated with lenalidomide and dexamethasone. |
+1q21, del(13q14), del(17p13),
t(4;14), t(11;14), and t(14;16) |
|
The prognostic significance of cytogenetics and
molecular profiling in multiple myeloma. |
-1p, +1q, del(13q), del(17p),
t(4;14)(p16;q32), t(11;14)(q13;q32), t(14;16)(q32;q23) |
|
The progression from MGUS to smoldering myeloma and
eventually to multiple myeloma involves a clonal
expansion of genetically abnormal plasma cells. |
+1q21, del(13q14), del(17p13),
t(11;14)(q13;q32), t(4;14)(p16;q32) |
|
Gains in 1q21 (+1q21) |
|
Gain of 1q21 is an unfavorable genetic prognostic
factor for multiple myeloma patients treated with
high-dose chemotherapy. |
+1q21, del(13)(q14), del(17)(p13),
t(4;14)(p16.3;q32), and t(11;14)(q13;q32) |
|
Chromosome 13 abnormalities |
|
Biological and prognostic
significance of interphase fluorescence in situ
hybridization detection of chromosome 13
abnormalities (delta13) in multiple myeloma: an
eastern cooperative oncology group study. |
Chromosome 13
abnormalities by FISH |
|
Deletion of 13q14 remains an
independent adverse prognostic variable in multiple
myeloma despite its frequent detection by interphase
fluorescence in situ hybridization. |
del(13q14) |
|
Prognostic impact of cytogenetic
and interphase fluorescence in situ
hybridization-defined chromosome 13 deletion in
multiple myeloma: early results of total therapy II. |
Chromosome 13
abnormalities by cytogenetics and FISH |
|
Chromosome 13 abnormalities
identified by FISH analysis and serum
beta2-microglobulin produce a powerful myeloma
staging system for patients receiving high-dose
therapy. |
Chromosome 13
abnormalities by FISH |
|
Chromosome 17 abnormalities |
|
p53 gene deletion detected by
fluorescence in situ hybridization is an adverse
prognostic factor for patients with multiple myeloma
following autologous stem cell transplantation. |
p53 deletions |
|
t(4;14)(p16;q32) |
|
|
t(4;14)(p16;q32) |
|
t(14;16)(q32;q23) |
|
Translocation t(14;16)
and multiple myeloma: is it really an independent
prognostic factor? |
t(14;16)(q32;q23) |
|
